Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127785 | 0.92 | RBP4 (0.47) | KDM4ETRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL5119805 | 0.89 | ALDH1A1 (0.50) | PHGDHMEN1KMT2AMAPTKDM4E | |
| SCHEMBL1457791 | 0.88 | TRPA1 (0.41) | TRPA1TRPV1KCNH2TRPM8RBP4 | |
| SCHEMBL5126853 | 0.87 | SMN1; SMN2 (0.51) | PHGDHMEN1KMT2AMAPTKDM4E | |
| SCHEMBL5120186 | 0.84 | KDM4E (0.52) | KDM4ETRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL5119463 | 0.83 | TRPA1 (0.47) | PHGDHMAPTTRPA1TRPV1KCNH2 | |
| SCHEMBL5115851 | 0.83 | TRPA1 (0.46) | TRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL5121480 | 0.81 | TRPA1 (0.51) | MAPTTRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL5112268 | 0.81 | RBP4 (0.47) | KDM4ETRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL5112970 | 0.81 | TRPV1 (0.54) | TRPA1TRPV1KCNH2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | claimed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | PHGDH 2036/4885MEN1 941/4885KMT2A 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.